Wegovy Injection, Solution
Product Images NDC 0169-4501

84 FDA label images from Novo Nordisk Pharmaceutical Industries, Lp · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 84 technical images submitted to the FDA as part of the official labeling for Wegovy (NDC 0169-4501). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novo Nordisk Pharmaceutical Industries, Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Structural-formula (Image 02)

Structural-formula (Image 02)
Chemical structure diagram of semaglutide, the active ingredient in the drug WEGOVY. The image depicts the molecular sequence and bonds of the peptide-based compound.*
FDA Label Image

Figure_2 (Figure 4)

Figure_2 (Figure 4)
A line graph showing the percentage of patients with an event over time (months) comparing WEGOVY Injection to placebo. The graph indicates a lower event rate for WEGOVY Injection over approximately 54 months. A hazard ratio (HR) of 0.80 with 95% confidence interval (0.72 to 0.90) is shown. Patient counts at risk are listed below the x-axis for both groups at multiple time points.*
FDA Label Image

Figure_3 (Figure 3)

Figure_3 (Figure 3)
A cumulative frequency plot comparing percent change in body weight for WEGOVY Injection versus placebo. The x-axis represents change in body weight (%) from -40 to +40, and the y-axis represents cumulative frequency percentage. The WEGOVY Injection curve shifts leftward indicating greater weight loss compared to the placebo curve.*
FDA Label Image

Figure_4 (Figure 4)

Figure_4 (Figure 4)
A cumulative frequency graph comparing change in body weight percentage between WEGOVY (semaglutide) injection and placebo groups. The x-axis represents percent change in body weight, ranging from -40% to +40%. The y-axis shows cumulative frequency percentage from 0% to 100%. Two curves illustrate that WEGOVY injection results in greater negative body weight change compared to placebo.*
FDA Label Image

Figure_5 (Figure 5)

Figure_5 (Figure 5)
A cumulative frequency graph comparing percentage change in body weight between WEGOVY Tablet and placebo groups. The x-axis represents change in body weight (%) ranging from -50% to +30%, and the y-axis shows cumulative frequency (%) from 0 to 100%. Two curves represent data: a solid line for WEGOVY Tablet and a dashed line for placebo, indicating differences in weight change distributions.*
FDA Label Image

Figure_6 (Figure 6 01)

Figure_6 (Figure 6 01)
A cumulative frequency graph depicting body weight percentage change from baseline, comparing Wegovy 7.2 mg injection, Wegovy 2.4 mg injection, and placebo. The x-axis shows body weight change percentage, while the y-axis represents cumulative frequency percentage, illustrating the distribution of weight changes among the groups.*
FDA Label Image

Figure_6 (Figure 6)

Figure_6 (Figure 6)
Two line graphs showing percent change in body weight over weeks for WEGOVY Injection and placebo groups. Both graphs plot change in body weight on the y-axis versus weeks on the x-axis. WEGOVY Injection results show a greater decrease in body weight compared to placebo in two different sample sizes indicated below each graph.*
FDA Label Image

Figure_7 (Figure 7)

Figure_7 (Figure 7)
Two line graphs depicting change in body weight (%) over weeks comparing WEGOVY injection versus placebo groups. The x-axes show weeks of treatment, and the y-axes show percent change in body weight. WEGOVY groups show greater weight reduction than placebo groups over time in both graphs, with final percent changes labeled at the ends of the curves.*
FDA Label Image

Figure_8 (Figure 8)

Figure_8 (Figure 8)
A line graph depicting percentage change in body weight over weeks for three groups: WEGOVY 1.7 mg Injection, WEGOVY 2.4 mg Injection, and Placebo. The x-axis represents weeks of treatment, while the y-axis shows percentage change in body weight. WEGOVY 2.4 mg Injection shows the greatest reduction in body weight over time, followed by WEGOVY 1.7 mg Injection, with Placebo showing minimal change.*
FDA Label Image

Figure_10 (Figure 10 01)

Figure_10 (Figure 10 01)
A line graph depicting the percent change in body weight over 72 weeks for Wegovy 7.2 mg injection, Wegovy 2.4 mg injection, and placebo groups. The x-axis represents weeks, and the y-axis shows the percentage change in body weight. Data points indicate a greater weight reduction over time with Wegovy 7.2 mg compared to Wegovy 2.4 mg and placebo.*
FDA Label Image

Figure_9 (Figure 9)

Figure_9 (Figure 9)
A line graph showing percent change in BMI over weeks comparing WEGOVY Injection and placebo. The x-axis is labeled Weeks with values from 0 to 68 and RD-MI. The y-axis shows Change in BMI (%) from -18 to 4. WEGOVY Injection shows a substantial decrease in BMI over time, while placebo remains near zero change. Sample sizes per group are listed below the x-axis for each time point.*
FDA Label Image

Figure_10 (Figure 10)

Figure_10 (Figure 10)
A cumulative frequency graph showing percentage change in BMI comparing WEGOVY injection and placebo. The x-axis represents change in BMI (%) from -50 to 20, and the y-axis represents cumulative frequency (%) from 0 to 100. The graph illustrates how the BMI changes differ between the WEGOVY injection (solid line) and placebo (dotted line) groups.*
FDA Label Image

Strength_bars (Strength Bars)

Strength_bars (Strength Bars)
WEGOVY semaglutide oral solution strengths displayed in a color-coded format: 0.25 mg/0.5 mL in blue, 0.5 mg/0.5 mL in pink, 1 mg/0.5 mL in yellow, 1.7 mg/0.75 mL in blue, and 2.4 mg/0.75 mL in purple, representing different dosage forms of this human prescription drug by Novo Nordisk Pharmaceutical Industries, LP.*
FDA Label Image

Image_overview (Image Overview)

Image_overview (Image Overview)
An instructional image showing a Wegovy (semaglutide) injection pen with the label visible, manufactured by Novo Nordisk. Below the pen, there is a diagram illustrating a pull-out action with the caption 'Pull out to get started,' guiding the user on how to prepare the pen for use.*
FDA Label Image

Wegovy_pen_parts (Wegovy Pen Parts)

Wegovy_pen_parts (Wegovy Pen Parts)
An instructional diagram illustrating the parts of the WEGOVY (semaglutide) injectable pen before and after use. Key features labeled include the expiration date location on the back, the pen window displaying dose colors, the needle cover concealing the needle, and the pen cap to be removed before injection. After use, the pen window shows the yellow bar stopped to confirm full dose delivery, and the needle cover locks in place.*
FDA Label Image

Pen_parts (Pen Parts)

Pen_parts (Pen Parts)
Instructional diagram showing the WEGOVY HD (semaglutide) injection pen with 7.2 mg/0.75 mL strength. The image compares the pen before and after use, highlighting label details such as expiration date, lot number, and dose strength. It points out the pen window status before and after injection, the needle cover location, and the pen cap removal step prior to injection. Guidance notes emphasize checking the medicine and dose, pen clarity, and needle safety features.*
FDA Label Image

Sharps-disposal (Image 01)

Sharps-disposal (Image 01)
A data table displaying weight in pounds and kilograms along the top and height in inches and centimeters down the side, with cells containing numerical values representing a calculated metric, with certain cells highlighted in green. The table appears structured for reference based on height and weight ranges.*
FDA Label Image

Injection-sites (Image 03)

Injection-sites (Image 03)
A horizontal dot plot showing relative exposure (Cavg) ratios with 90% confidence intervals for various intrinsic factors including sex (male), age groups (65-<75 years and >=75 years), race (Black or African American, Asian, American Indian or Alaska Native), ethnicity (Hispanic or Latino), body weight (74 kg and 143 kg), renal function (mild and moderate), and injection site (thigh and upper arm). The x-axis is logarithmic from 0.5 to 2.0, with a vertical line at 1.0 indicating the reference exposure level.*
FDA Label Image

Step4-injection (Image 04)

Step4-injection (Image 04)
A forest plot chart showing the relative exposure ratio and 90% confidence interval for various co-administered medications including Metformin, S-warfarin, R-warfarin, Digoxin, Atorvastatin, Ethinylestradiol, and Levonorgestrel. The chart compares AUC and Cmax values, with ratios centered around 1, indicating no significant change in exposure levels.*
FDA Label Image

Troubleshooting (Image 05)

Troubleshooting (Image 05)
A cumulative frequency graph comparing body weight change percentages between WEGOVY and placebo groups. The x-axis represents change in body weight (%) ranging from about -40% to +40%, and the y-axis shows cumulative frequency (%) from 0 to 100%. The graph includes two curves: one solid line labeled WEGOVY showing a higher body weight reduction than the dashed placebo line.*
FDA Label Image

Medicine-splash (Image 06)

Medicine-splash (Image 06)
A cumulative frequency plot illustrating change in body weight percentage, comparing WEGOVY (semaglutide) and placebo groups. The x-axis represents percent change in body weight, ranging from about -40% to +40%, and the y-axis shows cumulative frequency percentage from 0 to 100. Two curves depict weight change distributions for the WEGOVY and placebo treatments.*
FDA Label Image

Caution_circle (Image 07)

Caution_circle (Image 07)
This image shows two line graphs illustrating the percentage change in body weight over time (weeks and days) comparing WEGOVY and placebo groups. The Y-axis shows change in body weight percentage, and the X-axes show weeks and days. WEGOVY groups demonstrate greater weight reduction compared to placebo groups over the study periods.*
FDA Label Image

Phone_image (Export 00)

FDA Label Image

Hd_dosage (Dosage)

Hd_dosage (Dosage)
A dosage strength label for WEGOVY (semaglutide) showing 7.2 mg per 0.75 mL, presented in purple background with blue text, representing an oral tablet formulation.*
FDA Label Image

Wegovyhd_pen (Front Pen Image)

Wegovyhd_pen (Front Pen Image)
Instructional diagram for WEGOVY HD 2.4 mg semaglutide injection pen. The image shows the pen with a purple label and a gray cap, and includes a visual step indicating pulling out to get started. An arrow and folding guide are also depicted for usage instruction.*
FDA Label Image

Step_1 (Step 1)

Step_1 (Step 1)
Instructional diagram showing a hand holding a Wegovy 2.4 mg/0.75 mL pen injector, indicating the removal of the pen cap with a downward arrow toward a flat surface. The illustration appears to guide users on how to handle the injection pen properly before use.*
FDA Label Image

Injection_site (Step 2)

Injection_site (Step 2)
An instructional diagram showing a simplified human figure with highlighted areas for medication administration. The labeled injection or application sites include the upper arms, stomach, and upper legs, indicated on the figure's corresponding body parts.*
FDA Label Image

Step_4 (Step 4)

Step_4 (Step 4)
Injection instruction diagram for WEGOVY (semaglutide) showing how to use the pen device. It includes steps removing the pen cap to expose the needle, pressing the pen down during injection, and monitoring a yellow bar that stops moving when the injection is complete. The injection process takes about 5-10 seconds.*
FDA Label Image

Medication_splash (Medication Splash)

Medication_splash (Medication Splash)
An instructional illustration showing a hand holding a pen-like device labeled with a Novo Nordisk logo, positioned with its tip pointing down toward a surface. The word 'Medicine' points to the tip, indicating the release of medication from the device.*
FDA Label Image

Syringe-before-after (Syringe Before After)

Syringe-before-after (Syringe Before After)
Instructional illustration showing a prefilled glass syringe with labeled parts before use, including needle cap, label, plunger, glass barrel with medicine inside, and plunger rod. A second image shows the syringe after use with the needle exposed and the plunger fully depressed indicating injection completion.*
FDA Label Image

Supplies-needed (Supplies Needed)

Supplies-needed (Supplies Needed)
Illustration showing three items labeled for medical use: an alcohol wipe in a square packet, a cotton ball, and a sharps disposal container, each with a pointer to the respective item. The image appears instructional for proper preparation or disposal in a medical context.*
FDA Label Image

Image-1 (Ifu 1)

Image-1 (Ifu 1)
An instructional illustration showing a hand holding a prefilled syringe, likely related to administering a dose of WEGOVY (semaglutide). A black arrow points to the syringe barrel, emphasizing the area to observe or handle. A partially visible box is shown in the background.*
FDA Label Image

Image-2 (Ifu 2)

Image-2 (Ifu 2)
An instructional illustration showing a labeled medicine syringe with a visible expiration date window marked as EXP YYYY-MM-DD. The diagram highlights the medicine inside the syringe and identifies the location where the expiration date is displayed, likely related to the WEGOVY (semaglutide) injectable product.*
FDA Label Image

Image-3-injection-sites (Ifu 3)

Image-3-injection-sites (Ifu 3)
An injection site diagram showing recommended areas for administration: stomach area or thighs, and back of upper arm (with assistance). The illustration includes a figure highlighting these body areas in black and a close-up photo demonstrating the injection in the side of the abdomen.*
FDA Label Image

Image-4 (Ifu 4)

Image-4 (Ifu 4)
An instructional illustration showing a pair of hands preparing a syringe by attaching a needle. The left hand holds the needle cap while the right hand holds the syringe, demonstrating the step of connecting the needle to the syringe, with a black arrow pointing left to guide the action.*
FDA Label Image

Image-5 (Ifu 5)

Image-5 (Ifu 5)
Illustration showing a hand holding a syringe-like injector positioned at a 45-degree angle next to a person's abdomen, demonstrating the injection technique likely related to the administration of WEGOVY (semaglutide).*
FDA Label Image

Image-6 (Ifu 6)

Image-6 (Ifu 6)
An instructional illustration showing a person preparing an injection by drawing medication from a vial into a syringe. The inset image highlights the process of inserting the syringe needle into the vial to withdraw the liquid medication.*
FDA Label Image

Step_7 (Mpfs Step 7)

Step_7 (Mpfs Step 7)
An instructional illustration showing a hand holding a syringe at a 45-degree angle, about to administer an injection into the soft tissue of the abdomen, demonstrated by pinching the skin. This diagram visually guides the proper technique for subcutaneous injection.*
FDA Label Image

Image-8-disposal (Ifu 8)

Image-8-disposal (Ifu 8)
An instructional diagram showing a hand holding a syringe above a vial with an arrow indicating insertion of the syringe needle through the vial's rubber stopper for medication withdrawal or injection preparation.*
FDA Label Image

Flextouch_pen_image (Flextouch Pen Image)

Flextouch_pen_image (Flextouch Pen Image)
Illustration of the Wegovy FlexTouch pen and needle components with labeled parts including pen cap, pen window, dose counter, dose pointer, dose selector, dose button, outer and inner needle caps, needle, paper tab, flow check symbol, and dashed line used as a dosing guide.*
FDA Label Image

Image-a (Image A)

Image-a (Image A)
An illustration showing hands removing a cap step from a pen injector device. It is a step in preparing the device, likely related to a semaglutide injection product, WEGOVY by Novo Nordisk Pharmaceutical Industries, LP.*
FDA Label Image

Image-b (Image B)

Image-b (Image B)
Illustration showing a close-up of a hand holding a pen-like device, focusing on the tip section with a cap or nozzle, likely demonstrating a step in device usage or preparation.*
FDA Label Image

Image-c (Image C)

Image-c (Image C)
An instructional illustration showing two hands peeling off a protective cap from a pen-like device, with an arrow indicating the direction of removal.*
FDA Label Image

Image-d (Image D)

Image-d (Image D)
Instructional illustration depicting a hand twisting or unscrewing the cap of a pre-filled injection pen, suggesting preparation for subcutaneous injection. The image shows the top portion of the pen device with a finger grip on the cap.*
FDA Label Image

Image-e (Image E)

Image-e (Image E)
An instructional illustration showing a hand gripping the outer needle cap of an injection pen, with an arrow indicating the direction to remove the cap. The diagram labels the part as 'outer needle cap.'*
FDA Label Image

Image-f (Image F)

Image-f (Image F)
An instructional illustration showing a hand removing the inner needle cap from a pen injector. The image includes a labeled arrow pointing to the inner needle cap to be removed.*
FDA Label Image

Dose-counter (Dose Counter)

Dose-counter (Dose Counter)
WEGOVY 2.4 mg/0.75 mL injection carton by Novo Nordisk Pharmaceutical Industries, LP. The packaging shows semaglutide injection in a pen cartridge format, with a quantity of 3 cartridges indicated. The front displays the product name, strength, manufacturer, and a remark about single-patient use only.*
FDA Label Image

Image-g (Image G)

Image-g (Image G)
An instructional illustration showing a step for WEGOVY (semaglutide) injection pen use. The image depicts fingers holding the pen with a close-up of the flow check symbol display panel, indicated by an arrow, confirming the pen is ready for injection.*
FDA Label Image

Dose-zero (Dose Zero)

Dose-zero (Dose Zero)
WEGOVY semaglutide 2.4 mg/0.75 mL injection carton by Novo Nordisk Pharmaceutical Industries, LP. The label displays the proprietary name WEGOVY prominently, with the active ingredient semaglutide and strength 2.4 mg/0.75 mL indicated. The packaging is primarily white with green and gray text, showing the dosage form as injectable solution and including standard regulatory information.*
FDA Label Image

Dose-counter-zero (Dose Zero 01)

Dose-counter-zero (Dose Zero 01)
WEGOVY semaglutide oral tablet packaging label showing multiple available strengths including 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.5 mg/1, 1.7 mg/0.75 mL, 2.4 mg/0.75 mL, 25 mg/1, 3.2 mg/mL, 4 mg/1, 7.2 mg/0.75 mL, and 9 mg/1. The labeler is Novo Nordisk Pharmaceutical Industries, LP.*
FDA Label Image

Image-h (Image H)

Image-h (Image H)
An instructional illustration showing a hand holding and preparing a pen-style injection device, likely for a medication such as WEGOVY (semaglutide). The image highlights the step of removing or attaching the pen cap, indicated by a detailed inset and an upward arrow guide.*
FDA Label Image

Image-i (Image I)

Image-i (Image I)
An instructional diagram showing a person rotating a dosage selector on a semaglutide injection pen to select a 2.4 mg dose. The dose selection window displays "2.4 mg," indicating the chosen dose strength for administration.*
FDA Label Image

Dash-line (Dash Line)

Dash-line (Dash Line)
WEGOVY semaglutide oral solution injection pen carton with dose pens of varying strengths ranging from 0.25 mg/0.5 mL to 2.4 mg/0.75 mL. The packaging displays Novo Nordisk Pharmaceutical Industries as the labeler and includes multiple dose pens aligned horizontally with corresponding dosage markings.*
FDA Label Image

Image-j (Image J)

Image-j (Image J)
An instructional illustration showing hands manipulating a small vial or pen device, likely demonstrating how to prepare or use the product. The vial is labeled with partial text and arrows indicate a twisting or turning motion for use.*
FDA Label Image

Image-k (Image K)

Image-k (Image K)
An instructional illustration showing a hand holding a semaglutide pen injector with a dose counter reading '0 mg'. An arrow indicates turning the dial, accompanied by a close-up of the dose counter displaying '2.4 mg' and text stating 'Dose counter stopped: 2.4 mg left.' This likely demonstrates dose setting or adjustment for WEGOVY semaglutide injection.*
FDA Label Image

Injection-sites (Injection Sites)

Injection-sites (Injection Sites)
An illustration showing preferred injection sites on a human figure for medication administration. Highlighted areas include the upper arms, stomach, and upper legs. This guide is relevant for the use of WEGOVY (semaglutide) injections.*
FDA Label Image

Image-l (Image L)

Image-l (Image L)
An instructional illustration showing a hand holding a pen-like device, positioned at a downward angle over a surface, indicating the action of pressing down. The image likely depicts how to use or prepare a medication pen device, with the letter 'L' in the top left corner possibly indicating the left hand or a step label.*
FDA Label Image

Zero-dose (Dose Zero 02)

Zero-dose (Dose Zero 02)
WEGOVY semaglutide 2.4 mg/0.75 mL multi-dose pen injector packaging. The box is labeled for subcutaneous injection and includes the labeler Novo Nordisk Pharmaceutical Industries, LP. The packaging displays the proprietary name, active ingredient, strength, and a red and white color scheme with the brand logo.*
FDA Label Image

Dose-zero (Dose Zero 03)

Dose-zero (Dose Zero 03)
WEGOVY (semaglutide) injection labels showing multiple strengths including 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.5 mg/1 mL, 1.7 mg/0.75 mL, 2.4 mg/0.75 mL, 25 mg/1 mL, 3.2 mg/mL, 4 mg/1 mL, 7.2 mg/0.75 mL, and 9 mg/1 mL. The labeler is Novo Nordisk Pharmaceutical Industries, LP. The packaging primarily displays the product name, dosage strengths, volume, and manufacturer information on the injection vials.*
FDA Label Image

Image-m (Image M)

Image-m (Image M)
Illustration showing how to administer an oral medication by pressing down on a pen-style dispenser. The image includes a close-up of the dose indicator displaying '0 mg' and a hand holding the device while pressing downwards on an arm to deliver the dose.*
FDA Label Image

Image-n (Image N)

Image-n (Image N)
An instructional illustration showing a hand holding a pen-like device, likely an injection pen, with a speech bubble instructing to count slowly from one to six. The hand is positioned to demonstrate the dosing technique for a medication device, with emphasis on the timing of the count during administration.*
FDA Label Image

Dose-zero- (Dose Zero 04)

Dose-zero- (Dose Zero 04)
WEGOVY semaglutide oral tablets in a blister pack. Six tablets are visible, with two rows of three tablets each. The tablets are oblong and white. No additional text is visible on the blister pack in this image.*
FDA Label Image

Dose-zero (Dose Zero 05)

Dose-zero (Dose Zero 05)
WEGOVY oral tablet packaging label showing the brand name WEGOVY prominently. The label includes the active ingredient semaglutide. It displays available strengths and dosage forms as oral tablets, with various concentrations listed such as 0.25 mg/0.5 mL up to 9 mg/1. The manufacturer is Novo Nordisk Pharmaceutical Industries, LP.*
FDA Label Image

Image-o (Image O)

Image-o (Image O)
Instructional illustration showing the top part of a pen injector device with an upward-pointing arrow, indicating removal or upward movement of a component. The image is related to the WEGOVY (semaglutide) product administration process.*
FDA Label Image

Image-p (Image P)

Image-p (Image P)
An instructional illustration showing a hand gripping a pen-like device cap with an arrow indicating a twisting motion to remove or open the cap. The image suggests how to operate part of a drug delivery device, likely related to the WEGOVY medication pen.*
FDA Label Image

Image-q (Image Q)

Image-q (Image Q)
An instructional illustration showing a medication pen needle being disposed of into a sharps container, indicating proper disposal of sharps for safety.*
FDA Label Image

Image-r (Image R)

Image-r (Image R)
An instructional illustration showing hands holding a cylindrical device, with an arrow indicating the action of twisting or turning a cap or component on the device. The image likely depicts a step in using or preparing the WEGOVY medication delivery device.*
FDA Label Image

Image-s (Image S)

Image-s (Image S)
Illustration showing the removal of the outer needle cap from a pen injector device, indicated by two blue arrows. The image highlights the outer needle cap and the front part of the pen device, demonstrating a step in preparing the injection pen for use.*
FDA Label Image

0.25mg-carton (Image 17)

0.25mg-carton (Image 17)
WEGOVY 0.25 mg/0.5 mL injection by Novo Nordisk Pharmaceutical Industries, LP, presented as a single-dose prefilled pen for subcutaneous use. The carton provides dosage instructions to use WEGOVY once a week and contains four single-dose prefilled pens, each delivering 0.25 mg semaglutide. The packaging includes the product name, strength, route, usage instructions, and a support website (startwegovy.com).*
FDA Label Image

0.5 mg-carton (Image 18)

0.5 mg-carton (Image 18)
Packaging label for WEGOVY 0.5 mg (semaglutide) injection 0.5 mg/0.5 mL by Novo Nordisk Pharmaceutical Industries. The label shows a box containing 4 single-dose prefilled pens for subcutaneous use only, with instructions to use WEGOVY once a week. The image includes dosage information, product illustrations, and the Novo Nordisk logo.*
FDA Label Image

1mg-carton (Image 19)

1mg-carton (Image 19)
WEGOVY 1 mg semaglutide injection in single-dose prefilled pens. The package includes 4 prefilled pens, each delivering 1 mg/0.5 mL for subcutaneous use. The label indicates use once a week and is manufactured by Novo Nordisk Pharmaceutical Industries, LP. The design features a white and brown color scheme with product and dosing information.*
FDA Label Image

1.7mg-carton (Image 20)

1.7mg-carton (Image 20)
WEGOVY 1.7 mg (semaglutide) injection carton with 4 single-dose prefilled pens. The label shows dosage strength 1.7 mg per 0.75 mL, with instructions to use once weekly for subcutaneous injection. The manufacturer is Novo Nordisk Pharmaceutical Industries, LP. The packaging includes a blue and white color scheme with product and usage information.*
FDA Label Image

2.4mg-carton (Image 21)

2.4mg-carton (Image 21)
WEGOVY 2.4 mg (semaglutide) injection 2.4 mg/0.75 mL single-dose prefilled pens by Novo Nordisk Pharmaceutical Industries, LP. The carton contains 4 single-dose prefilled pens for subcutaneous use and instructs use of WEGOVY once a week. The packaging prominently shows the product name, dosage strength, and pen illustration, with usage instructions and support website startwegovy.com.*
FDA Label Image

Hd_carton (Image 09)

Hd_carton (Image 09)
Wegovy packaging label showing multiple dosage strengths of semaglutide in injectable form. Visible strength options include 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL. Each strength is displayed in a distinct rectangular color block. The label is produced by Novo Nordisk Pharmaceutical Industries, LP.*
FDA Label Image

Carton-0-25 (Carton 0 25)

Carton-0-25 (Carton 0 25)
WEGOVY 0.25 mg (semaglutide) injection, 0.25 mg/0.5 mL, in a carton containing 4 single-dose prefilled syringes. Label indicates subcutaneous use, prescription only, manufactured by Novo Nordisk Pharmaceutical Industries, LP. The label features an image of the prefilled syringe and usage instructions to use Wegovy once weekly.*
FDA Label Image

Carton-0-5 (Carton 0 5)

Carton-0-5 (Carton 0 5)
Wegovy 0.5 mg (semaglutide) injection prefilled syringe carton. Each 0.5 mg/0.5 mL single-dose syringe is for subcutaneous use and contains semaglutide. The package contains 4 single-dose prefilled syringes. Labeler is Novo Nordisk Pharmaceutical Industries, LP. The label instructs use once a week and includes medication guide dispensing information.*
FDA Label Image

Carton-1mg (Carton 1mg)

Carton-1mg (Carton 1mg)
Packaging label for Wegovy 1 mg (semaglutide) injection in a 0.5 mL single-dose prefilled syringe. The label indicates 4 prefilled syringes per carton and specifies subcutaneous use only. It includes dosing instructions to use Wegovy once weekly and is labeled by Novo Nordisk Pharmaceutical Industries, LP.*
FDA Label Image

Carton-1-7 (Carton 1 7)

Carton-1-7 (Carton 1 7)
Packaging label for Wegovy (semaglutide) injection 1.7 mg/0.75 mL prefilled syringes by Novo Nordisk Pharmaceutical Industries, LP. The label shows a carton containing 4 single-dose prefilled syringes intended for subcutaneous use. The front and side panels display the brand name, strength, dosage form, dosing frequency of once weekly, and manufacturer information along with an image of the syringe.*
FDA Label Image

Carton-2-4 (Carton 2 4)

Carton-2-4 (Carton 2 4)
Wegovy 2.4 mg (semaglutide) injection in prefilled syringes. The label indicates a strength of 2.4 mg/0.75 mL for subcutaneous use. The packaging contains 4 single-dose prefilled syringes (0.75 mL each) and is labeled for prescription use. Manufactured by Novo Nordisk Pharmaceutical Industries, LP.*
FDA Label Image

Flextouch_carton (Flextouch Carton)

Flextouch_carton (Flextouch Carton)
Wegovy FlexTouch injection pen carton label for semaglutide 9.6 mg/3 mL (3.2 mg/mL) oral tablet form, 2.4 mg per dose. The label indicates single-patient-use, includes 1 pen delivering 4 doses, with NovoFine Plus 32G needles. Manufactured by Novo Nordisk Pharmaceutical Industries, LP. The label also details weekly dosing and injection instructions.*
FDA Label Image

Wegovy_tablets_1-5mg_carton (Image 10)

Wegovy_tablets_1-5mg_carton (Image 10)
Illustration showing a WEGOVY (semaglutide) injection pen with labeled instruction to 'Pull out to get started.' Below the pen image is a diagram depicting a sectioned component, likely indicating how to prepare or activate the pen prior to use.*
FDA Label Image

Wegovy_tablets_4mg_carton (Wegovy Tablets 4mg Carton)

Wegovy_tablets_4mg_carton (Wegovy Tablets 4mg Carton)
Packaging label for WEGOVY 4 mg (semaglutide) tablets, an oral prescription drug by Novo Nordisk. The label includes the proprietary name, strength, dosage form, and quantity of 30 tablets. It also features dosage recommendations, storage instructions, inactive ingredients, and patient directions such as taking on an empty stomach with water and waiting 30 minutes before other oral intake.*
FDA Label Image

Wegovy_tablets_9mg_carton (Wegovy Tablets 9mg Carton)

Wegovy_tablets_9mg_carton (Wegovy Tablets 9mg Carton)
The image shows the packaging label for WEGOVY 9 mg (semaglutide) tablets by Novo Nordisk Pharmaceutical Industries, LP. The label provides dosage strength, quantity of 30 tablets, and usage instructions including taking on an empty stomach with no more than 4 ounces of water and waiting 30 minutes before eating or taking other medications. It includes storage guidelines, child-resistant bottle warning, ingredient information, and contact details for the manufacturer.*
FDA Label Image

Wegovy_tablets_25mg_carton (Wegovy Tablets 25mg Carton)

Wegovy_tablets_25mg_carton (Wegovy Tablets 25mg Carton)
Wegovy 25 mg (semaglutide) tablets packaging label includes the product name, strength, and dosage form. The 30-tablet bottle is child-resistant and labeled with storage instructions, recommended dosage guidance, and inactive ingredients. The labeler is Novo Nordisk Pharmaceutical Industries, LP, with product and patent information, a barcode, and guidance to dispense with medication guide.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.